Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat breast cancer: zanidatamab trial launches

NCT ID NCT06435429

Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether a new drug called zanidatamab, given with chemotherapy, works better than the current standard treatment (trastuzumab plus chemo) for people with metastatic HER2-positive breast cancer that has worsened after prior therapy. About 550 adults will take part. The main goal is to see if the new combination delays cancer growth or improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zanidatamab (a drug given by IV) combined with chemotherapy
What this could lead to
If it works, this could offer a new treatment option for people with HER2-positive breast cancer that has spread and stopped responding to current therapies.
What could go wrong
This is a large phase 3 trial, but the experimental drug may not improve survival or delay cancer growth compared to the standard treatment. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 550 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants are eligible to be included in the study only if all of the following criteria apply: 1. Is 18 years of age or of the legal adult age per local standard at the time of signing the informed consent. 2. Has histologically confirmed HER2-positive breast cancer according to ASCO-CAP Guidelines as evaluated by a sponsor-designated central laboratory 3. Participants with unresectable or metastatic HER2 positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment. 4. Must have received at least 2 lines of HER2-directed therapy for their metastatic disease. 1. Prior HER2-targeted neo-adjuvant or adjuvant therapy that resulted in relapse within 6 months of the completion of therapy will be considered a line of treatment for metastatic disease. 2. Based on the physician's choice, participants' eligibility, and institutional and local guidelines, participants may also have received post-T-DXd therapy, for example, a tucatinib-based regimen and/or T-DM1. 3. Participants must not have received more than 4 lines of HER2-directed therapy in the metastatic setting. 5. Has measurable disease per RECIST version 1.1. 6. Is eligible to receive one of the chemotherapy options listed in the physician's choice of chemotherapy (eribulin, gemcitabine, vinorelbine, or capecitabine). 7. Participants with history of treated or clinically inactive CNS metastases are eligible as specified in the protocol. 8. Has a life expectancy of at least 6 months, in the opinion of the investigator. 9. Has adequate hematologic parameters as defined in the protocol. 10. Has adequate hepatic function as specified in the protocol. 11. Has creatinine clearance ≥ 50 mL/minute as calculated per local institutional guidelines. 12. Has LVEF ≥ 50% as determined by either echocardiogram or MUGA obtained within 4 weeks before the first dose of study intervention. 13. Has ECOG performance status of 0 or 1. 14. Participant agrees to the following based on sex assigned at birth. 1. Male participants: Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 7 months after the last dose of study intervention or the contraception period for the combination chemotherapy of choice per local guidance/standard practice: * Refrain from donating fresh unwashed semen. * Use contraception as follows as specified in the protocol 2. Female participants: * A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: * Is a women of nonchildbearing potential OR * Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year), with low user dependency during the study intervention period and for at least 7 months after the last dose of study intervention. * A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 3 days before the first dose of study intervention. * Additional requirements for pregnancy testing during and after study intervention are provided in the protocol. * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. 15. Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the protocol. Participants are excluded from the study if any of the following criteria apply: Medical Conditions 1. Has clinically confirmed leptomeningeal disease, in the opinion of the investigator. 2. Has uncontrolled or significant cardiovascular disease. 3. Has toxicity related to prior cancer therapy that has not resolved to ≤ Grade 1, with exceptions as stated in the protocol. 4. Has uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. 5. Has an infection with HIV-1 or HIV-2, with the exception of participants with well-controlled HIV. 6. Has active hepatitis B or C infection. 7. Has an active SARS-CoV-2 infection. Participants with prior infection that has resolved per local institutions' requirements and screening guidance are eligible. 8. Has a history of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in the drug formulation of zanidatamab. 9. Is unable to receive trastuzumab treatment due to medical contraindications. 10. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site. 11. Has any condition that would prevent treatment with the physician's choice of chemotherapy. 12. Has any issue or condition that in the opinion of the investigator would contraindicate the participant's participation in the study or confound the results of the study. Prior/Concomitant Therapy 13. Has a history of prior allogeneic bone marrow, stem cell, or solid organ transplantation. 14. The washout periods for prior anticancer therapies before randomization as specified in the protocol. 15. Has a history of trauma or major surgery within 4 weeks prior to randomization. Other Exclusions 16. Has a known hypersensitivity to any components of the study drugs, including chemotherapy. 17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic HER2-positive breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic HER2-positive breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    163 sites in 15 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP HM Hopital de La Timone

    RECRUITING

    Marseille, 13005, France

  • AZ Delta- Campus Rumbeke

    RECRUITING

    Roeselare, 8800, Belgium

  • Abramson Cancer Center of The University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Aichi Cancer Center

    RECRUITING

    Nagoya, 464-8681, Japan

  • Aretaieio Hospital

    RECRUITING

    Athens, 11528, Greece

  • Arizona Oncology Tucson - Wilmot

    WITHDRAWN

    Tucson, Arizona, 85711, United States

  • Asst Papa Giovanni Xxiii

    RECRUITING

    Bergamo, 24127, Italy

  • Athens Medical Center

    RECRUITING

    Athens, 15125, Greece

  • Azienda Ospedaliero Universitaria Di Bologna Policlinico S Orsola Malpighi Via Massarenti

    RECRUITING

    Bologna, 40138, Italy

  • Azienda Ospedaliero Universitaria di Modena

    RECRUITING

    Modena, 41124, Italy

  • BC Cancer-Vancouver Center

    RECRUITING

    Vancouver, V5Z 4E6, Canada

  • Beatson West Of Scotland Cancer Centre

    RECRUITING

    Glasgow, G12 0YN, United Kingdom

  • Białostockie Centrum Onkologii im. Marii Skłodowskiej-Curie w Białymstoku

    RECRUITING

    Bialystok, 15-027, Poland

  • Blue Ridge Cancer Care

    RECRUITING

    Roanoke, Virginia, 24014, United States

  • Box Hill Hospital

    RECRUITING

    Melbourne, Victoria, 3128, Australia

  • CHU UCL Namur - Site Sainte-Elisabeth

    RECRUITING

    Namur, 5000, Belgium

  • CHU de Québec Université Laval Hôpital du Saint Sacrement

    RECRUITING

    Québec, G1S 4L8, Canada

  • CHUVI - H.U. Alvaro Cunqueiro

    RECRUITING

    Vigo, 36312, Spain

  • Catarina Pesquisa Clinica

    RECRUITING

    Itajaí, 88301-220, Brazil

  • Centre François Baclesse

    RECRUITING

    Caen, 14000, France

  • Centre Georges François Leclerc

    RECRUITING

    Dijon, 21000, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59020, France

  • Centro Regional Integrado de Oncologia

    RECRUITING

    Ceará, 60336-232, Brazil

  • Ceon Pesquisas Ltda

    RECRUITING

    São Caetano do Sul, 09541-270, Brazil

  • Charring Cross Hospital

    RECRUITING

    London, W6 8RF, United Kingdom

  • Chiba Cancer Center

    RECRUITING

    Chiba, 260-8717, Japan

  • Churchill Hospital

    RECRUITING

    Oxford, OX3 7LJ, United Kingdom

  • Columbia University Medical Center 161 Fort Washington

    RECRUITING

    New York, New York, 10032-3729, United States

  • DASA Hospital Brasilia

    RECRUITING

    Brasília, 71.635-610, Brazil

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215-5418, United States

  • Duke Cancer Institute

    RECRUITING

    Durham, North Carolina, 27710-2000, United States

  • European Interbalkan Medical Center

    RECRUITING

    Thessaloniki, 57001, Greece

  • Florida Cancer Specialists Research East

    RECRUITING

    West Palm Beach, Florida, 33401, United States

  • Florida Cancer Specialists Research North

    RECRUITING

    St. Petersburg, Florida, 33705, United States

  • Florida Cancer Specialists Research South

    RECRUITING

    Fort Myers, Florida, 33901, United States

  • Fondazione IRCCS Policlinico San Matteo

    RECRUITING

    Pavia, 27100, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    RECRUITING

    Monza, 20900, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    RECRUITING

    Rome, 00136, Italy

  • Fox Chase Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19111, United States

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Froedtert and The Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Fukushima Medical University Hospital

    RECRUITING

    Fukushima, 960-1295, Japan

  • Gachon University Gil Medical Center

    RECRUITING

    Namdong-gu, 21565, South Korea

  • Gangnam Severance Hospital, Yonsei University Health System

    RECRUITING

    Seoul, 06273, South Korea

  • Grand Hôpital de Charleroi

    RECRUITING

    Gilly, 6060, Belgium

  • Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

  • Guy's Hospital

    RECRUITING

    London, SE1 9RT, United Kingdom

  • HPS Pharmacies - Adelaide

    RECRUITING

    Adelaide, 5000, Australia

  • Hackensack Meridian Health

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Helios Klinikum Berlin Buch GmbH Klinik für Gynäkologie und Geburtshilfe

    RECRUITING

    Berlin, 13125, Germany

  • Hospital Beata Maria Ana

    RECRUITING

    Madrid, 28007, Spain

  • Hospital Beneficiencia Portuguesa

    RECRUITING

    São Paulo, 01323-030, Brazil

  • Hospital Clinic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Clinico San Carlos

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, 46010, Spain

  • Hospital General Universitario de Elche

    RECRUITING

    Elche, 03203, Spain

  • Hospital Nossa Senhora Da Conceição

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul PUCRS

    RECRUITING

    Porto Alegre, 90610-001, Brazil

  • Hospital Universitari Vall d Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario A Coruña

    RECRUITING

    A Coruña, 15006, Spain

  • Hospital Universitario Clinico San Cecilio

    RECRUITING

    Granada, 18016, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    RECRUITING

    Madrid, 28040, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, 41013, Spain

  • Hospital Universitario de Badajoz

    RECRUITING

    Badajoz, 06006, Spain

  • Hospital Universitario de Canarias

    RECRUITING

    San Cristóbal de La Laguna, 38320, Spain

  • ICANS - Institut de cancérologie Strasbourg Europe

    RECRUITING

    Strasbourg, 67000, France

  • ICO Badalona-H.U. Germans Trias i Pujol

    RECRUITING

    Barcelona, 08916, Spain

  • IEPE Unimed Sorocaba

    RECRUITING

    Sorocaba, São Paulo, 18060-105, Brazil

  • IRCCS Centro di Riferimento Oncologico di Aviano CRO

    RECRUITING

    Aviano, 33081, Italy

  • IRCCS Istituto Clinico Humanitas

    RECRUITING

    Rozzano, 20089, Italy

  • Institut Bergonie

    RECRUITING

    Bordeaux, 33076, France

  • Institut Paoli Calmettes

    RECRUITING

    Marseille, 13009, France

  • Institute Jules Bordet

    RECRUITING

    Anderlecht, 1070, Belgium

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre

    RECRUITING

    Portalegre, 90050-170, Brazil

  • Istituto Europeo di Oncologia

    RECRUITING

    Milan, 20141, Italy

  • Istituto Oncologico Veneto - I.R.C.C.S.

    RECRUITING

    Padova, 35128, Italy

  • Jewish General Hospital

    RECRUITING

    Montreal, H3T 1E2, Canada

  • Juntendo University Hospital

    RECRUITING

    Tokyo, 113-8431, Japan

  • Kanagawa Cancer Center

    RECRUITING

    Yokohama, 241-8515, Japan

  • Klinikum Wels-Grieskirchen GmbH - Abteilung für Innere Medizin IV

    RECRUITING

    Wels, 4600, Austria

  • Kyoto University Hospital

    RECRUITING

    Kyoto, 606-8507, Japan

  • LMU Klinikum - Apotheke

    RECRUITING

    München, 81377, Germany

  • Leicester Royal Infirmary

    RECRUITING

    Leicester, LE2 7LX, United Kingdom

  • Los Angeles Hematology Oncology Medical Group Glendale

    RECRUITING

    Glendale, California, 91204, United States

  • MD Anderson Cancer Center

    RECRUITING

    Madrid, 28033, Spain

  • Marienhospital Bottrop gGmbH

    RECRUITING

    Dortmund, 44263, Germany

  • Maryland Oncology Hematology Healing Way - USOR

    RECRUITING

    Irving, Texas, 75063, United States

  • Mayo Clinic - PPDS

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic Jacksonville - PPDS

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Scottsdale - PPDS

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Medical Oncology Hematology Consultants

    RECRUITING

    Irving, Texas, 75063, United States

  • Medizinische Universitat Innsbruck

    RECRUITING

    Innsbruck, 6020, Austria

  • Medizinische Universitat Wien

    RECRUITING

    Vienna, 1090, Austria

  • Medstar Georgetown University Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • Memorial Sloan Kettering

    RECRUITING

    Long Island City, New York, 11101, United States

  • Messino Cancer Center

    RECRUITING

    Asheville, North Carolina, 28806, United States

  • Millennium Research and Clinical Development

    WITHDRAWN

    Houston, Texas, 77090, United States

  • Minnesota Oncology Hematology

    RECRUITING

    Coon Rapids, Minnesota, 55433, United States

  • Nagoya City University Hospital

    RECRUITING

    Nagoya, 467-8602, Japan

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy w Warszawie

    RECRUITING

    Warsaw, 02-781, Poland

  • National Cancer Center Hospital

    RECRUITING

    Chūōku, 104-0045, Japan

  • National Hospital Organization Hokkaido Cancer Center

    RECRUITING

    Sapporo, 003-0804, Japan

  • National Hospital Organization Kyushu Cancer Center

    RECRUITING

    Fukuoka, 811-1395, Japan

  • National Hospital Organization Osaka National Hospital

    RECRUITING

    Osaka, 540-0006, Japan

  • New Cross Hospital

    RECRUITING

    Wolverhampton, WV10 0QP, United Kingdom

  • Nexus Health

    RECRUITING

    Irving, Texas, 75063, United States

  • Nucleo de Oncologia Da Bahia

    RECRUITING

    Salvador, 40.170-070, Brazil

  • Okayama University Hospital

    RECRUITING

    Okayama, 700-8558, Japan

  • Onco Star Sp Oncologia LTDA

    RECRUITING

    São Paulo, 04062-001, Brazil

  • Oncology Hematology Care (OHC)

    RECRUITING

    Cincinnati, Ohio, 45226, United States

  • Oncopôle Claudius Regaud Pharmacie

    RECRUITING

    Toulouse, 31059, France

  • Ordensklinikum Barmherzige Schwestern

    RECRUITING

    Linz, 4010, Austria

  • Osaka International Cancer Institute

    RECRUITING

    Chūōku, 541-8567, Japan

  • Ospedale San Raffaele S.r.l PPDS

    RECRUITING

    Milan, 20132, Italy

  • Peninsula and South Eastern Haematology and Oncology Group

    RECRUITING

    Mount Waverly, Victoria, 3149, Australia

  • Perlmutter Cancer Center 160 E 34th St

    RECRUITING

    New York, New York, 10016-4744, United States

  • Pharmacie Centre de Cancerologie de la Sarthe

    RECRUITING

    Le Mans, 72000, France

  • Pharmacie ICM Val d'Aurelle

    RECRUITING

    Montpellier, 34298, France

  • Pratia MCM Kraków

    RECRUITING

    Krakow, 30-727, Poland

  • Pratia Poznan

    RECRUITING

    Poznan, 60-192, Poland

  • Real Hospital Portugues de Beneficiencia Em Pernambuco

    RECRUITING

    Recife, 52.010-075, Brazil

  • Rhode Island Hospital

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Rocky Mountain Cancer Centers

    RECRUITING

    Denver, Colorado, 80218, United States

  • Royal United Hospital

    RECRUITING

    Bath, BA1 3NG, United Kingdom

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Sagara Hospital

    RECRUITING

    Kagoshima, 892-0833, Japan

  • Saint Luke's Cancer Institute

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • Saitama Medical University International Medical Center

    RECRUITING

    Hidaka-shi, 350-1298, Japan

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

  • Sansum Clinic 540 W - USOR

    RECRUITING

    Irving, Texas, 75063, United States

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, 13605, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System

    RECRUITING

    Seoul, 03722, South Korea

  • Showa University Hospital

    RECRUITING

    Tokyo, 142-8666, Japan

  • Soon Chun Hyang University Cheonan Hospital

    RECRUITING

    Cheonan-si, 330721, South Korea

  • St John of God Hospital Subiaco

    RECRUITING

    Subiaco, 6008, Australia

  • Sunnybrook Research Institute

    RECRUITING

    Toronto, M4N 3M5, Canada

  • Sunshine Coast University Private Hospital

    RECRUITING

    Birtinya, Queensland, 4575, Australia

  • Texas Oncology - Fort Worth

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Texas Oncology Gulf Coast

    RECRUITING

    Irving, Texas, 75063, United States

  • Texas Oncology West

    RECRUITING

    Irving, Texas, 75063, United States

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    RECRUITING

    Seoul, 137-701, South Korea

  • The Christie - PPDS

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The Kinghorn Cancer Centre

    RECRUITING

    Mount Kuring-Gai, 2080, Australia

  • The Mount Sinai Hospital

    RECRUITING

    New York, New York, 10029, United States

  • The Oncology Institute Of Hope And Innovation

    RECRUITING

    Cerritos, California, 90703, United States

  • The Ottawa Hospital Cancer Centre

    RECRUITING

    Ottawa, K1H 8L6, Canada

  • Tokai University Hospital

    RECRUITING

    Isesaki-shi, 259-1193, Japan

  • U.T. MD Anderson Cancer Center, Investigational Pharmacy Services

    RECRUITING

    Houston, Texas, 77030, United States

  • UCSF at Mission Bay MB

    RECRUITING

    San Francisco, California, 94158, United States

  • UNC Central Investigational Drug Services

    RECRUITING

    Morrisville, North Carolina, 27560, United States

  • USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS

    RECRUITING

    Los Angeles, California, 90033, United States

  • UZ Antwerpen

    RECRUITING

    Edegem, 2650, Belgium

  • University General Hospital of Patras

    RECRUITING

    Pátrai, 26504, Greece

  • University Hospitals Cleveland Medical Center 11100 Euclid Ave

    WITHDRAWN

    Cleveland, Ohio, 44106-1716, United States

  • University of Arizona Cancer Center

    RECRUITING

    Tucson, Arizona, 85719, United States

  • University of Colorado-Cancer Center-PPDS

    RECRUITING

    Aurora, Colorado, 80045-2517, United States

  • Universitätsklinikum Carl Gustav Carus an der TU

    RECRUITING

    Dresden, 01307, Germany

  • Universitätsklinikum Ulm

    RECRUITING

    Ulm, 89081, Germany

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    RECRUITING

    Poznan, 60-569, Poland

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Virginia Oncology Associates, Sentara Health

    RECRUITING

    Norfolk, Virginia, 23502, United States

  • Washington Cancer Center

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • Wojewódzki Szpital Specjalistyczny W Białej Podlaskiej

    RECRUITING

    Biała Podlaska, 21-500, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.